TD Cowen analyst Tyler Van Buren maintains $Regeneron Pharmaceuticals (REGN.US)$ with a buy rating, and maintains the target price at $1,230.
According to TipRanks data, the analyst has a success rate of 44.3% and a total average return of 2.9% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Regeneron Pharmaceuticals (REGN.US)$'s main analysts recently are as follows:
Regeneron's third-quarter results surpassed expectations on revenue and more significantly in EPS. However, the performance of the Eylea franchise was a predominant concern. The impending introduction of a biosimilar version of Eylea's standard dose by a competitor casts doubt on the future of the franchise. This includes the potential underappreciated rate of erosion for the standard dose and possible impact on the high dose variant.
The recent decline in Regeneron's share value is viewed as an excessive response to the latest developments concerning Pavblu, the less than favorable projections for Q4 Eylea HD, and the absence of clear communication regarding future growth prospects for Eylea.
The recent decline in Regeneron's stock post-Q3 earnings took many by surprise, as it was thought that the near- and long-term consensus estimates for the ophthalmology franchise were overly optimistic. Despite this, it is believed that the intrinsic value of Regeneron's fundamentals remains significantly higher than the current share price.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
